IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM

BACKGROUND: Immune checkpoint inhibitors (ICIs) are not uniformly effective in glioblastoma treatment. Immunogenomic determinants may identify patients who are most likely to benefit from these therapies. Therefore, we compared the immunogenomic phenotype of a responder to combination anti-LAG-3 and...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Jackson, Christina, Choi, John, Zhang, JiaJia, Piotrowski, Anna, Walbert, Tobias, Desai, Arati, Ahluwalia, Manmeet, Nabors, Burt, Ye, Xiaobu, Desideri, Serena, Fisher, Joy, Wen, Patrick, Grossman, Stuart, Smith, Kellie, Pardoll, Drew, Lim, Michael
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847812/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.511
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires